Shared Decision-Making and MHT Safety in Women with VMS

In this episode, "Shared Decision Making and MHT Safety in Women with VMS," two menopause experts explore the multifaceted challenges of initiating menopause hormone therapy (MHT) in patients who present with hesitation, prior misinformation, and complex risk profiles. The experts acknowledge that for many patients — particularly African American women who face racial disparities in care and systemic barriers to treatment — delayed presentation and eroded trust in the medical system are significant obstacles. They emphasize the importance of directly addressing WHI-era misinformation by walking patients through the actual data, using visual aids, patient handouts, and resources from the Menopause Society to support shared decision-making across multiple visits rather than trying to compress the conversation into a single appointment.

The discussion turns to onset of action for transdermal estradiol and micronized progesterone, with the experts noting that while full therapeutic effect may take up to three months, many patients begin to notice meaningful improvements within the first few weeks — particularly with sleep. More subtle changes, such as improvements in mood, cognition, and irritability, tend to emerge gradually and are often recognized retrospectively at follow-up visits.

The experts also address how updated regulatory guidance has shifted patient conversations, with some women now arriving having heard that estrogen carries no risks at all — requiring clinicians to recalibrate expectations in both directions. The episode closes with a discussion of cardiovascular risk stratification, highlighting the value of tools such as the PREVENT calculator, coronary artery calcium scoring, and advanced lipid markers. The experts stress that when cardiovascular complexity exceeds the scope of a generalist's practice, referral to a preventive cardiologist or menopause specialist is both appropriate and beneficial, reinforcing the team-based approach to care.

The next episode in this series, "Treatment Response Monitoring and Subspecialty Referral for VMS," features the panelists discussing tailored safety monitoring strategies for a patient with cardiovascular risk factors on MHT, and examining how primary care, gynecology, cardiology, and endocrinology can work together to deliver comprehensive, prevention-focused VMS care.